

- **Name:** Dr Aaron C. Tan
  - **Current Position & Affiliation:** Senior Resident Physician, Division of Medical Oncology, National Cancer Centre Singapore
  - **Country:** Singapore
- 

- **Educational Background:**

- BSc(Med)Hons (NSW), MBBS (NSW), PhD (Syd), FRACP

- **Professional Experience:**

- Internal Medicine & Medical Oncology specialty training (2013-2018)  
Royal North Shore Hospital, Melanoma Institute Australia, North Shore Private Hospital, Sydney Adventist Hospital (Sydney, Australia)
- Clinical Fellowship (2018-2019)  
Division of Medical Oncology, National Cancer Centre Singapore
- Resident Physician (2019-2021)  
Division of Medical Oncology, National Cancer Centre Singapore
- Senior Resident Physician (2021-current)  
Division of Medical Oncology, National Cancer Centre Singapore
- Instructor (2021-current)  
DukeNUS Medical School, National University of Singapore

- **Professional Organizations:**

- Medical Oncology Group of Australia (MOGA)
- Clinical Oncology Society of Australia (COSA)
- European Society of Medical Oncology (ESMO)
- American Society of Clinical Oncology (ASCO)
- International Association for the Study of Lung Cancer (IASLC)
- Asian Thoracic Oncology Research Group (ATORG)

- **Main Scientific Publications:**

2020 to present only (# indicates joint first author)

- **Tan AC, Tan DSW.** Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. *J Clin Oncol*, 2021 (doi: 10.1200/JCO.21.01626).
- **Tan AC, Boggs DH, Lee EQ, et al.** Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases. *Frontiers in Oncology*, 2022 (doi: 10.3389/fonc.2021.780379).

15<sup>th</sup> Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

- Lee J#, **Tan AC**#, Zhou S, et al. Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005). *JTO Clin Res Rep*, 2021;3:100261.
- **Tan AC**. Tumor-Agnostic Biomarkers: Heed Caution, and Why Cell of Origin Still Matters. *Onco*, 2021;1:95-100.
- Taslimi S, Brar K, Ellenbogen Y, Deng J, Hou W, Moraes FY, Glantz M, Zacharia BE, **Tan AC**, Ahluwalia MS, Khasraw M, Zadeh G, Mansouri A. Comparative Efficacy of Systemic Agents for Brain Metastases From Non-Small-Cell Lung Cancer With an EGFR Mutation/ALK Rearrangement: A Systematic Review and Network Meta-Analysis. *Frontiers in Oncology*, 2021;11:5101.
- Singh K, Batich KA, Wen PY, **Tan AC**, et al. Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. *Clin Canc Res*, 2021 (doi: 10.1158/1078-0432.CCR-21-2681).
- Suteja L, Yeong J, **Tan AC**, Toy W, Tan DSW. Improving Precision and Implementation of Immuno-Oncology Biomarkers. *J Thorac Oncol*, 2021 (doi: 10.1016/j.jtho.2021.08.016).
- Dimitriou F, Lo SN, **Tan AC**, et al. FDG-PET to predict long-term outcome from anti-PD1 therapy in metastatic melanoma. *Ann Oncol*, 2021 (doi: 10.1016/j.annonc.2021.10.003).
- Brar K, Taslimi S, Ellenbogen Y, Deng J, Hou W, Moraes FY, Glantz M, Zacharia BE, **Tan AC**, Ahluwalia MS, Khasraw M, Zadeh G, Mansouri A. Comparative efficacy of treatments for brain metastases from non-small-cell lung cancer without an EGFR-mutation/ALK-rearrangement: a systematic review and network meta-analysis. *World Neurosurg*, 2021 (doi: 10.1016/j.wneu.2021.10.113).
- Minchom A, **Tan AC**, Massarelli E, et al. Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-small Cell Lung Cancer in the Phase 1/2 LIBRETTO-001 Trial. *Oncologist*, 2021 (doi: 10.1002/onco.13976)
- Isaacs J, **Tan AC**, Hanks BA, et al. Clinical Trials with Biologic Primary Endpoints in Immunoncology: Concepts and Usage. *Clin Canc Res*, 2021 (doi: 10.1158/1078-0432.CCR-21-1593).
- Yeong J, Suteja L, Simoni Y, Lau KW, **Tan AC**, et al. Intra-tumoral CD39+CD8+ T cells predict response to PD-1/PD-L1 blockade in patients with NSCLC. *J Thorac Oncol*, 2021 (doi: 10.1016/j.jtho.2021.04.016)
- Seet AOL#, **Tan AC**#, Tan TJY, et al. Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study—An Asian Tertiary Cancer Center Experience. *JCO Prec Onc*, 2021;5:859-875.
- **Tan AC**, Bagley SJ, Wen PY, et al. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. *J Immunother Cancer*, 2021;9:e002459.
- Chua KP#, Teng Y#, **Tan AC**#, et al. Integrative Profiling of T790M Negative EGFR Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities. *Clin Canc Res*, 2021 (doi: 10.1158/1078-0432.CCR-20-4607).
- **Tan AC**, Chan J, Khasraw M. The role for immunotherapy in fusion-driven lung cancer. *Expert Rev Anticancer Ther*, 2021;21:461-4.
- Srinivasan ES, **Tan AC**, Anders CK, et al. Salting the soil: Targeting the microenvironment of brain metastases. *Mol Cancer Ther*, 2021;20:455-66.

15<sup>th</sup> Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

- **Tan AC**, Loh TJ, Kwang XL, Tan GS, Lim KH, Tan DSW. Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib. Lung Cancer (Auckl), 2021;12:11-20.
- Lin JJ, Liu SV, McCoach CE, Zhu VW, **Tan AC**, et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol, 2020;31:1725-33.
- **Tan AC**, Seet AOL, Lai GGY, et al. Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC. J Thorac Oncol, 2020;12:1928-34.
- Broom A, Kenny K, Page A, Cort N, Lipp ES, **Tan AC**, et al. The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts. Clin Cancer Res, 2020;26:5809-13.
- **Tan AC**, Ashley DM, Lopez GY, Malinzak M, Friedman H, Khasraw M. Management of glioblastoma – state of the art and future directions. CA Cancer J Clin, 2020;70:299-312.
- **Tan AC**, Ashley DM, Khasraw M. Adapting to a pandemic - conducting oncology trials during the SARS-CoV-2 pandemic. Clin Cancer Res, 2020;26:3100-03.
- **Tan AC**, Lai GGY, Tan GS, et al. Utility of incorporating next generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost effectiveness analysis. Lung Cancer, 2020;139:207-15.
- **Tan AC**, Itchins M, Khasraw M. Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers. Int J Mol Sci, 2020;21:E1416.
- **Tan AC**. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). Thorac Cancer, 2020;11:511-8.
- Anderson KJ#, **Tan AC**#, Parkinson J, Back M, Kastelan M, Newey A, Brewer J, Wheeler H, Hudson AL, Amin SB, Johnson KJ, Barthel FP, Verhaak RGW, Khasraw M. Molecular and clonal evolution in recurrent metastatic gliosarcoma. Cold Spring Harb Mol Case Stud, 2020;6:a004671.